FREE SHIPPING ON ORDERS OVER $150

tirzepatide pdufa FDA confirms shortage is still over, gives compounders a grace period tm242296d1_ex99-1img006.jpg

$25.55

Quantity
- +
Description

Understanding why patients remain still hungry helps normalize the experience and prevents premature discontinuation

tirzepatide pdufa FDA confirms shortage is still over, gives compounders a grace period tm242296d1_ex99-1img006.jpg

In SURMOUNT-1, nausea occurred in 30.5% of participants on 15 mg tirzepatide versus 10.0% on placebo, and vomiting occurred in 12.8% versus 2.3% (NEJM 2022)

tirzepatide pdufa FDA confirms shortage is still over, gives compounders a grace period tm242296d1_ex99-1img006.jpg

For optimal results with tirzepatide, adhering to a healthy diet is essential

tirzepatide pdufa FDA confirms shortage is still over, gives compounders a grace period tm242296d1_ex99-1img006.jpg

Retatrutide is still being studied for potential cardiac side effects (increased heart rate)

tirzepatide pdufa FDA confirms shortage is still over, gives compounders a grace period tm242296d1_ex99-1img006.jpg

ULN, upper limit of normal

tirzepatide pdufa FDA confirms shortage is still over, gives compounders a grace period tm242296d1_ex99-1img006.jpg

You may also like

recommand products